(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India

Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical Pricing Authority

New Delhi, the 10th November, 2016

ORDER

S.O. 3431(E) In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 644(E), dated 2nd March, 2016, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

SI. No.	Name of the Scheduled Formulation	Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Pheniramine Injection	Pheniramine-22.75mg/ml	1 ml	1.03
2.	Naloxone Injection	Naloxone-0.4 mg/ml	1 ml	80.49
3.	Lorazepam Injection	Lorazepam-2mg/ml	1 ml	7.22
4.	Phenytoin Injection	Phenytoin-25 mg/ml	1 ml	2.33
5.	Ceftazidime Powder for Injection	Ceftazidime-250 mg	Each pack	60.39
6.	Ceftazidime Powder for Injection	Ceftazidime-1 gm	Each pack	194.19
7.	Artesunate + (Sulphadoxine+ Pyrimethamine) Tablet	Artesunate-50mg + (Sulphadoxine + Pyrimethamii 500mg+25 mg)	Combi Pack ne	19.69
8.	Metoclopramide Oral Liquid	Metoclopramide 5mg/ml	1 ml	0.41
9.	Streptokinase Injection	Streptokinase 7,50,000 IU	Each Pack	1168.12
10.	Streptokinase Injection	Streptokinase 15,00,000 IU	Each Pack	1660.84
11.	Povidone Iodine Solution	Povidone Iodine-5%	1 ml	0.33
12.	Betamethasone Cream	Betamethasone 0.05%	1 gm	0.54
13.	Tropicamide Eye Drop	Tropicamide 1%	1 ml	9.34
14.	Cetrimide Solution	Cetrimide 20% (concentrate for dilution)	1 ml	0.29
15.	Mannitol Injection	Mannitol 20%	1 ml	0.27
16.	Ranitidine Injection	Ranitidine-25 mg/ml	1 ml	1.48
17.	Dicyclomine Injection	Dicyclomine-10 mg/ml	1 ml	2.44
18.	Ciprofloxacin Ointment	Ciprofloxacin-0.3%	1 gm	1.04
19.	Gentamicin Drops	Gentamicin-0.3%	1 ml	0.84
20.	Pilocarpine Drops	Pilocarpine-2%	1 ml	9.38
21.	Timolol Drops	Timolol-0.25%	1 ml	4.79
22.	Atropine Drops	Atropine-1%	1 ml	3.05
23.	Homatropine Drops	Homatropine-2%	1 ml	5.53
24.	Betamethasone Injection	Betamethasone-4 mg/ml	1 ml	3.89
25.	Hydrocortisone Injection	Hydrocortisone-200 mg	Each Pack	53.39
26.	Rifampicin Tablet	Rifampicin-300 mg	1 Tablet	2.72

27.	Fluconazole Capsule	Fluconazole-100 mg	1 Capsule	23.44
28.	Fluconazole Capsule	Fluconazole-200 mg	1 Capsule	33.87
29.	Efavirenz Capsule	Efavirenz-200 mg	1 Capsule	21.43
30.	Efavirenz Capsule	Efavirenz-600 mg	1 Capsule	55.81
31.	Ritonavir Capsule	Ritonavir-100 mg	1 Capsule	26.18
32.	Paracetamol Suppository	Paracetamol 80mg	1 Suppository	6.04
33.	Paracetamol Suppository	Paracetamol 170mg	1 Suppository	7.14
34.	Paracetamol Oral Liquid	Paracetamol 125mg/5ml	1 ml	0.31

Note:

- (a) All the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- (c) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS.
- (e) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (f) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (g) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (h) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/170/38/2016/F

F. No. 8(38)/2016/D.P./NPPA-Div.-II

(BALJIT SINGH) Assistant Director